奥美拉唑联合生长抑素治疗SAP的临床疗效和安全性

Efficacy and safety of omeprazole combined with somatostatin in treatment of severe acute pancreatitis

目的:考察奥美拉唑联合生长抑素治疗重症急性胰腺炎(severe acute pancreatitis,SAP)的临床疗效和安全性,为该类疾病的治疗提供临床参考.方法:以我院2008-03/2013-06收治的140例SAP患者为研究对象,随机平均分为研究组和对照组.对照组给予常规治疗,研究组在常规治疗的基础上加用奥美拉唑和生长抑素.考察两组的有效率、并发症发生率等,并进行对比分析.结果:研究组和对照组的有效率分别为94.29%和77.14%,组间差异具有统计学意义(P<0.05).研究组和对照组的住院时间(18.4 d±1.3 d vs 25.3 d±1.7 d)和胃肠道功能恢复时间(2.1 d±1.2 d vs 3.6 d±1.5 d)等相比,差异具有统计意义(P<0.05),以研究组更为理想.研究组和对照组的并发症总发生率(7.14%vs25.71%)、死亡率(2.86%vs 11.43%)以及器官功能衰竭的发生率相比,组间差异具有统计学意义(P<0.05).结论:奥美拉唑联合生长抑素能够加速SAP患者的康复进程,且可降低SAP患者并发症的发生率和死亡率,临床安全性良好.

AIM： To investigate the efficacy and safety of omeprazole combined with somatostatin in the treatment of severe acute pancreatitis （SAP）. METHODS： One hundred and forty patients with SAP treated at our hospital from March 2008 to June 2013 were randomly divided into either a study group or a control group. The control group received conventional treatment, and the study group was treated with omepra- zole and somatostatin on the basis of conven- tional therapy. The efficacy and the incidence of complications were compared between the two groups. RESULTS： The response rate was significantly higher in the study group than in the control group （94.29% vs 77.14%, P 〈 0.05）. Comparedwith the control group, the time to gastrointes- tinal function recovery （18.4 d ± 1.3 d vs 25.3 d ± 1.7 d） and the hospitalization time （2.1 d ± 1.2 d vs 3.6 d± 7.5 d） were significantly shorter in the study group （P 〈 0.05 for both）. The overall incidence of complications （7.14% vs 25.71%）, mortality （2.86% vs 11.43%） and the incidence of organ failure also differed significantly between the two groups （P 〈 0.05 for all）. CONCLUSION： Omeprazole combined with so- matostatin could accelerate recovery and reduce the incidence of complications in SAP patients.